Alternative Therapies for People Who Distrust Big Pharma

J&J Pharm: Five Forces Continued

Power of Customers

The power of customers refers to the degree of influence that customers have over a company and its products. In the pharmaceutical industry, customers include both individual consumers and healthcare providers, such as hospitals and clinics. Customers in the pharmaceutical industry have significant power due to a few reasons:

High Switching Costs

In the pharmaceutical industry, customers often have to use a specific drug to treat a certain condition, and switching to another drug may not be an option. This is especially true for patients who are dependent on specific drugs to manage chronic conditions. As a result, customers are less likely to switch to a competitor\\\\\\\'s product, giving them more bargaining power (Janssen, 2019).

Information Availability

Due to the availability of information online and through healthcare providers, customers are becoming more knowledgeable about their healthcare needs and options (Eysenbach, 2000). This increased knowledge makes them more informed when making decisions about their treatment, which can lead to increased bargaining power.

Healthcare Provider Influence

Healthcare providers also have significant bargaining power due to their ability to influence the prescribing decisions of patients. Doctors and other healthcare providers can choose to prescribe or not prescribe a certain drug, which can greatly affect the sales and success of a pharmaceutical company.

Threat of Substitute Products

The threat of substitute products refers to the likelihood of customers switching to a competitor\\\\\\\'s product or a substitute product that serves the same purpose. In the pharmaceutical industry, the threat of substitute products can come from a variety of sources, including:

Generic Drugs

When a drug\\\\\\\'s patent expires, other companies can start producing generic versions of the drug at a lower cost, which can lead to decreased sales for the original drug. Johnson and Johnson must consider this threat when developing new drugs and setting prices for existing ones (Janssen, 2019).

Alternative Therapies